Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 25,281	$ 44,411
Money market funds	104,095	$ 213,699
License fee receivable	200,000
Advances on research and development contract services, including $185,392 and $202,816 from Theradex at December 31, 2015 and 2014, respectively	207,677	$ 231,177
Prepaid expenses and other current assets	60,922	50,012
Total current assets	597,975	539,299
Total assets	597,975	539,299
Current liabilities:
Accounts payable and accrued expenses	159,076	122,534
Research and development contract liabilities, including $88,162 and $18,436 to Theradex at December 31, 2015 and 2014, respectively	124,566	$ 58,186
Dividend payable on Series A Convertible Preferred Stock	$ 2,000
Due to Chairman and major stockholder		$ 92,717
Total current liabilities	$ 285,642	$ 273,437
Stockholders' equity:
Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 175,000 shares authorized, issued and outstanding at December 31, 2015; aggregate redemption value of $8,750,000; liquidation preference based on assumed conversion into common shares; 2,187,500 shares of common stock issuable upon conversion	1,750,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 47,875,814 shares and 45,483,097 shares at December 31, 2015 and 2014, respectively	4,787	$ 4,548
Additional paid-in capital	17,129,815	15,979,475
Accumulated deficit	(18,572,269)	(15,718,161)
Total stockholders' equity	312,333	265,862
Total liabilities and stockholders' equity	$ 597,975	$ 539,299